StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — IDBI Capital

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))10 Sept 2026via IDBI Capital Research Calls Telegram

Entry₹1,954Stated
Target₹2,090
Total upside +6.96% (call closed)
Stop loss₹1,889-3.33% risk
Exit₹2,09018 Sept 2026, 3:30 pm
Target hit+6.96%0.00%upside left
Follow IDBI Capital for new calls(26% target hit, 389 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 209 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 18 Sept 2026
4 supporting3 neutral0 opposing
Supports the BUY call (4)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·18 Sept · today

Emcure Pharma: Here's Why ICICI Direct Calls It A High-Conviction 'Buy'

NewsNdtv-Profit·7 Sept · 2w ago

(opens in new tab)

Broker’s call: Emcure Pharma (Buy)

NewsHbl·4 Sept · 2w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·8 Jul · 2mo ago

Neutral / worth noting (3)

Market Trading Guide: Acme Solar, Bharat Dynamics among 5 stock recommendations for Wednesday

NewsEt-Markets·15 Sept · 2d ago

(opens in new tab)

Market Trading Guide: Emcure Pharma among 2 stock recommendations for Monday

NewsEt-Markets·6 Sept · 2w ago

(opens in new tab)

Coal India, Emcure Pharma, Finolex Cables, GIC, Gulf Oil Lubricants Dividends: Last Day To Buy Shares To Qualify

NewsNdtv-Profit·3 Sept · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from IDBI Capital

Every call and its outcome